|
1）Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res. 1996; 13: 671-82
|
|
|
|
2）Brem H, Piantadosi S, Burger PC, et al. The Polymer-brain Tumor Treatment Group: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995; 345: 1008-12
|
|
|
|
|
|
3）National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology- Central Nervous System Cancers Clinical Practice Guidelines in Oncology v. 1. 2013
|
|
|
|
|
|
4）National Cancer Institute Cancer Information Physician Data Query -(May, 2012)
|
|
|
|
|
|
5）National Institute for Health and Clinical Excellence (June, 2007)
|
|
|
|
|
|
6）Brem H, Langer R. Polymer-based drug delivery to the brain. Science and Medicine. 1996; 3: 52-61
|
|
|
|
|
|
7）Tamada JA, Langer R. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci U S A. 1993; 90: 552-6
|
|
|
|
|
|
8）ノーベルファーマ株式会社 社内資料．ヒト神経膠芽腫細胞株の頭蓋内移植モデルに対するカルムスチンの抗腫瘍効果
|
|
|
|
|
|
9）Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymerimplant in the monkey brain. Cancer Res. 1998; 58: 672-84
|
|
|
|
|
|
10）Aoki T, Nishikawa R, Sugiyama K, et al; for the NPC-08 study group. A Multicenter Phase I/II Study of the BCNU Implant (Gliadel® Wafer) for Japanese Patients with Malignant Gliomas. Neurologia medico-chirurgica. accepted by the Editorial Board
|
|
|
|
|
|
11）ノーベルファーマ株式会社 社内資料．カルムスチンのヒト肝ミクロソーム及びサイトソールを用いたin vitro代謝試験
|
|
|
|
|
|
12）DeVita VT, Denham C, Davidson JD, et al. The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in man and animals. Clin Pharmacol Ther. 1967; 8: 566-77
|
|
|
|
|
|
13）Brunton L, Lazo J, Parker K. Goodman and Gilmanʼs The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006. p.1324
|
|
|
|
|
|
14）ノーベルファーマ株式会社 社内資料．ラット及びウサギにおけるポリフェプロサン20の薬物動態
|
|
|
|
|
|
15）ノーベルファーマ株式会社 社内資料．添加物ポリマーの毒性試験
|
|
|
|
|
|
16）Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoper-ative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995; 345: 1008-12
|
|
|
|
|
|
17）Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5: 79-88
|
|
|
|
|
|
18）Westphal M, Ram Z, Riddle V, et al. Executive Committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006; 148: 269-75
|
|
|
|
|
|
19）La Rocca RV, Vitaz TW, Morassutti DJ, et al. A Phase II Study of Radiation with Concomitant and then Sequential Temozolomide(TMZ) in Patients with Newly Diagnosed Supratentorial High-grade Malignant Glioma Who Have Undergone Surgery with Carmustine (BCNU) Wafer Insertion. Neuro Oncol. 2006; 8: 391-500
|
|
|
|
|
|
20）Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008; 88: 353-7
|
|
|
|
|
|
21）McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009; 110; 583-8
|
|
|
|
|
|
22）Affronti ML, Heary CR, Herndon JE 2nd, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009; 115: 3501-11
|
|
|
|
|
|
23）Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010; 33: 441-9
|
|
|
|
|
|
24）Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Neuro-oncology Club of the French Society of Neurosurgery. Ann Surg Oncol. 2010; 17: 1740-6
|
|
|
|
|
|
25）Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol. 2000; 53: 220-4
|
|
|
|
|
|
26）McGirt MJ, Villavicencio AT, Bulsara KR, et al. Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. J Neurosurg. 2002; 96: 941-5
|
|
|
|
|
|
27）Hammoud DA, Belden CJ, Ho AC, et al. The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging. AJR Am J Roentgenol. 2003; 180: 1469-75
|
|
|
|
|